Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354069 | 0.88 | CCR9 (0.50) | CCR9METAP2KMT2AMAPTKDM4E | |
| SCHEMBL27699 | 0.87 | CCR9 (0.58) | CCR9METAP2KMT2AMAPTKDM4E | |
| SCHEMBL13137546 | 0.84 | CCR9 (0.52) | CCR9METAP2KMT2AMAPTKDM4E | |
| SCHEMBL29077 | 0.75 | LMNA (0.65) | CCR9METAP2KMT2AMAPTLMNA | |
| SCHEMBL30318 | 0.75 | MPO (0.51) | KMT2AMAPTMEN1TDP1LMNA | |
| SCHEMBL27998 | 0.74 | LMNA (0.67) | CCR9METAP2KMT2AMAPTKDM4E | |
| SCHEMBL27058 | 0.73 | LMNA (0.57) | CCR9KMT2AMAPTKDM4ELMNA | |
| SCHEMBL27861 | 0.73 | LMNA (0.60) | CCR9KMT2AMAPTKDM4EMEN1 | |
| SCHEMBL23447719 | 0.73 | BCL2L1 (0.56) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL3985583 | 0.73 | METAP2 (0.72) | METAP2KMT2AKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402310-A1 | CCR9 inhibitors and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| EP-2399903-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | claimed |
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | claimed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | claimed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | claimed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1507756-A4 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | claimed |
| JP-2005526857-A | — | — | 2005-09-08 | — | — | JP | claimed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| EP-1507756-B1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20050137179-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2005-06-23 | — | — | US | disclosed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885METAP2 2446/4885KMT2A 4473/4885 |
| US-20050137179-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | CCR9 14/4885METAP2 1563/4885KMT2A 4477/4885 |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885METAP2 2446/4885KMT2A 4473/4885 |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885METAP2 2446/4885KMT2A 4473/4885 |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885METAP2 2446/4885KMT2A 4473/4885 |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | CCR9 14/4885METAP2 1563/4885KMT2A 4477/4885 |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885METAP2 2446/4885KMT2A 4473/4885 |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885METAP2 2446/4885KMT2A 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.